Evogene (EVGN) Assets Average (2025 - 2026)
Evogene (EVGN) posted Assets Average of $10.0 million for Q1 2026, down 56.51% sequentially from $23.1 million in Q4 2025, and down 72.95% YoY from $37.1 million in Q1 2025.
Evogene (EVGN) Assets Average (2025 - 2026) Analysis & Trends
Evogene has reported Assets Average for 2 years, with the latest figure at $10.0 million in Q1 2026.
- Quarterly Assets Average fell 72.95% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 72.95% YoY) and the FY2025 annual result came in at $30.0 million, down 34.14% from the prior year.
- Assets Average retreated to $10.0 million in Q1 2026 per EVGN's latest filing, from $23.1 million in the prior quarter.
- Over five years, Assets Average peaked at $37.1 million in Q1 2025 and troughed at $10.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 10.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.03 Mn |
| Dec 31, 2025 | 23.07 Mn |
| Sep 30, 2025 | 30.01 Mn |
| Jun 30, 2025 | 34.12 Mn |
| Mar 31, 2025 | 37.08 Mn |